Regen BioPharma Inc (RGBP)
0.6100
-0.05
(-7.58%)
USD |
OTCM |
May 06, 15:36
Regen BioPharma Cash from Financing (Quarterly): 0.1629M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.1629M |
| December 31, 2023 | 0.1658M |
| September 30, 2023 | 0.1437M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.10M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.0005M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -0.0945M |
| September 30, 2021 | 1.411M |
| June 30, 2021 | -0.0479M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.0053M |
| December 31, 2019 | -0.0318M |
| September 30, 2019 | 0.143M |
| June 30, 2019 | 0.054M |
| March 31, 2019 | 0.1035M |
| Date | Value |
|---|---|
| December 31, 2018 | 0.1313M |
| September 30, 2018 | 0.4183M |
| June 30, 2018 | 0.1115M |
| March 31, 2018 | 0.1729M |
| December 31, 2017 | 0.619M |
| September 30, 2017 | 0.4914M |
| June 30, 2017 | 0.7057M |
| March 31, 2017 | 0.2423M |
| December 31, 2016 | 0.7002M |
| September 30, 2016 | 0.283M |
| June 30, 2016 | 0.4451M |
| March 31, 2016 | 0.375M |
| December 31, 2015 | 0.5553M |
| September 30, 2015 | 0.169M |
| June 30, 2015 | 0.075M |
| March 31, 2015 | 0.7365M |
| December 31, 2014 | 0.2507M |
| September 30, 2014 | 0.141M |
| June 30, 2014 | 0.095M |
| March 31, 2014 | 0.05M |
| December 31, 2013 | 0.345M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.0945M
Minimum
Dec 2021
1.411M
Maximum
Sep 2021
0.1006M
Average
--
Median
Jun 2020
Cash from Financing (Quarterly) Benchmarks
| CervoMed Inc | -0.0934M |
| GlucoTrack Inc | 0.00 |
| AIM ImmunoTech Inc | 0.147M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | -0.043M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.2093M |
| Free Cash Flow | -0.4821M |
| Free Cash Flow Per Share (Quarterly) | -0.0531 |
| Free Cash Flow to Equity (Quarterly) | -0.189M |
| Free Cash Flow Yield | -21.14% |